The program was clearly explained last year by the outgoing CEO of MHRA when she discussed "highly personalized" treatments.
They are talking about vaccines being made by computer analysis of genetic makeup of the tumor. By current regulator practice, that would make every dose a different drug and thus could never be approved. This is a framework discussion on how to regulate these.
The only reason MRNa is being mentioned is that is the only tech currently in play in the space. But the program would be applied to any other program using the same concept of creating a different vaccine per person based on genetics, regardless of underlying common tech.
Even the MHRA/regulators try to prolong the decision. And people here want us to believe that the world and human society fight fair and square? That principle never existed. Greed and self-preservation are more prominent than what simple-minded people like the long- cult think.
DCVax-L is not an mRNA therapy – It is a personalized dendritic cell-based cancer vaccine, meaning it does not fall under the scope of this consultation, which focuses on mRNA-based therapies. If anything. The fact that MHRA is proactively addressing regulatory pathways for novel cancer treatments indicates a general willingness to support innovative therapies like DCVax-L.
H2R you asked "Is this yet another attempt to side line NWBO?" No, it seems to be a general alert to all stakeholders. But rest assured if NWBO could find a way to fuck it up, it's almost guaranteed they will. Imo
I think there are more issues/concerns with mRNA vaccines so longer term followup is likely warranted. L has a very long history of safety, mRNA not so much. Best wishes.